Skip to main content
Erschienen in: Inflammation 2/2012

01.04.2012

Visfatin Levels in Behcet’s Disease

verfasst von: Hatice Sezen, Seydi Okumus, Yavuz Pehlivan, Ismail Dilli, Mehmet Tarakcioğlu, Ahmet Mesut Onat

Erschienen in: Inflammation | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of our study is to determine the serum visfatin levels of patients with Behcet’s disease and to investigate the relationship between visfatin, an adipokine released from adipose tissue, levels and activity of Behcet’s disease. Fifty-eight patients with Behcet’s disease were enrolled to the study. Nineteen of the patients were inactive, and 39 of them were active. We enrolled 30 healthy subjects as being control group. Visfatin and tumor necrosis factor alpha (TNF-α) levels were measured with ELISA method. Visfatin levels were significantly lower in patients with Behcet’s disease whose illnesses were active or inactive than the control group (p < 0.05). There was no significant difference between the active patient and inactive patient group. The reason for the lower levels of serum visfatin in active and inactive patients’ group could be due to pro-inflammatory cytokines such as TNF-α and IL-6 which suppress genetic expression of visfatin in patients with Behcet’s disease, or else.
Literatur
1.
Zurück zum Zitat Bonfioli, A.A., and F. Orefice. 2005. Behcet’s disease. Seminars in Ophthalmology 20(3): 199–206.PubMedCrossRef Bonfioli, A.A., and F. Orefice. 2005. Behcet’s disease. Seminars in Ophthalmology 20(3): 199–206.PubMedCrossRef
2.
Zurück zum Zitat Akdeniz, N., M. Esrefoglu, M.S. Keleş, A. Karakuzu, and M. Atasoy. 2004. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Annals of the Academy of Medicine, Singapore 33: 596–599.PubMed Akdeniz, N., M. Esrefoglu, M.S. Keleş, A. Karakuzu, and M. Atasoy. 2004. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Annals of the Academy of Medicine, Singapore 33: 596–599.PubMed
3.
Zurück zum Zitat Hamzaoui, K., A. Hamzaoui, F. Guemira, M. Bessioud, M. Hamza, and K. Ayed. 2002. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scandinavian Journal of Rheumatology 31: 205–210.PubMedCrossRef Hamzaoui, K., A. Hamzaoui, F. Guemira, M. Bessioud, M. Hamza, and K. Ayed. 2002. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scandinavian Journal of Rheumatology 31: 205–210.PubMedCrossRef
4.
Zurück zum Zitat Adam, B., and E. Calikoglu. 2004. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. Journal of the European Academy of Dermatology and Venereology 18: 318–320.PubMedCrossRef Adam, B., and E. Calikoglu. 2004. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. Journal of the European Academy of Dermatology and Venereology 18: 318–320.PubMedCrossRef
5.
Zurück zum Zitat Aridogan, B.C., M. Yildirim, V. Baysal, H.S. Inaloz, K. Baz, and S. Kaya. 2003. Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet’s disease. The Journal of Dermatology 30: 602–607.PubMed Aridogan, B.C., M. Yildirim, V. Baysal, H.S. Inaloz, K. Baz, and S. Kaya. 2003. Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet’s disease. The Journal of Dermatology 30: 602–607.PubMed
6.
Zurück zum Zitat Doğanavşargil, E., and G. Keser. 2005. Behçet Hastalığı. Türkiye Klinikleri Dergisi Behçet Hastalığı özel sayısı. Doğanavşargil, E., and G. Keser. 2005. Behçet Hastalığı. Türkiye Klinikleri Dergisi Behçet Hastalığı özel sayısı.
7.
Zurück zum Zitat Luk, T., Z. Malam, and J.C. Marshall. 2008. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. Journal of Leukocyte Biology 83: 804–816.PubMedCrossRef Luk, T., Z. Malam, and J.C. Marshall. 2008. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. Journal of Leukocyte Biology 83: 804–816.PubMedCrossRef
8.
Zurück zum Zitat Evereklioglu, C., H.S. Inaloz, N. Kırtak, S. Doganay, M. Bülbül, B. Otlu, et al. 2002. Serum leptin concentration is increased in patients with Behcet’s syndrome and is correlated with disease activity. The British Journal of Dermatology 147: 331–336.PubMedCrossRef Evereklioglu, C., H.S. Inaloz, N. Kırtak, S. Doganay, M. Bülbül, B. Otlu, et al. 2002. Serum leptin concentration is increased in patients with Behcet’s syndrome and is correlated with disease activity. The British Journal of Dermatology 147: 331–336.PubMedCrossRef
9.
Zurück zum Zitat Jayachandran, N.V., L. Rajasekhar, P.K. Chandrasekhara, S. Kanchinadham, and G. Narsimulu. 2008. Multiple peripheral arterial and aortic aneurysms in Behcet's syndrome: a case report. Clinical Rheumatology 27: 265–267.PubMedCrossRef Jayachandran, N.V., L. Rajasekhar, P.K. Chandrasekhara, S. Kanchinadham, and G. Narsimulu. 2008. Multiple peripheral arterial and aortic aneurysms in Behcet's syndrome: a case report. Clinical Rheumatology 27: 265–267.PubMedCrossRef
10.
Zurück zum Zitat Bardak, Y., and B.C. Aridoğan. 2004. The demonstration of serum interleukin 6–8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocular Immunology and Inflammation 12: 53–58.PubMedCrossRef Bardak, Y., and B.C. Aridoğan. 2004. The demonstration of serum interleukin 6–8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocular Immunology and Inflammation 12: 53–58.PubMedCrossRef
11.
Zurück zum Zitat Otero, M., R. Lago, R. Gomez, F. Lago, C. Dieguez, J.J. Gómez-Reino, et al. 2006. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 65: 1198–1201.PubMedCrossRef Otero, M., R. Lago, R. Gomez, F. Lago, C. Dieguez, J.J. Gómez-Reino, et al. 2006. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 65: 1198–1201.PubMedCrossRef
12.
Zurück zum Zitat Matsui, H., A. Tsutsumi, M. Sugihara, T. Suzuki, K. Iwanami, M. Kohno, et al. 2008. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 67: 571–572.PubMedCrossRef Matsui, H., A. Tsutsumi, M. Sugihara, T. Suzuki, K. Iwanami, M. Kohno, et al. 2008. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 67: 571–572.PubMedCrossRef
13.
Zurück zum Zitat Brentano, F., O. Schorr, C. Ospelt, J. Stanczyk, R.E. Gay, S. Gay, et al. 2007. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis and Rheumatism 56: 2829–2839.PubMedCrossRef Brentano, F., O. Schorr, C. Ospelt, J. Stanczyk, R.E. Gay, S. Gay, et al. 2007. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis and Rheumatism 56: 2829–2839.PubMedCrossRef
14.
Zurück zum Zitat Reinehr, T., C. Roth, T. Menke, and W. Andler. 2004. Adiponectin before and after weight loss in obese children. JCEM 89: 3790–3794.PubMed Reinehr, T., C. Roth, T. Menke, and W. Andler. 2004. Adiponectin before and after weight loss in obese children. JCEM 89: 3790–3794.PubMed
15.
Zurück zum Zitat Moschen, A.R., A. Kaser, B. Enrich, B. Mosheimer, M. Theurl, H. Niederegger, et al. 2007. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology 178: 1748–1758. Moschen, A.R., A. Kaser, B. Enrich, B. Mosheimer, M. Theurl, H. Niederegger, et al. 2007. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology 178: 1748–1758.
Metadaten
Titel
Visfatin Levels in Behcet’s Disease
verfasst von
Hatice Sezen
Seydi Okumus
Yavuz Pehlivan
Ismail Dilli
Mehmet Tarakcioğlu
Ahmet Mesut Onat
Publikationsdatum
01.04.2012
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9328-2

Weitere Artikel der Ausgabe 2/2012

Inflammation 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.